BioCentury | Aug 3, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: July 2017

New Therapeutic Targets and Biomarkers: July 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2017. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Jul 10, 2017
Distillery Therapeutics

Cancer

INDICATION: Head and neck cancer Patient sample, cell culture and mouse studies suggest inhibiting the long non-coding RNA (lncRNA) MIR31HG could help treat oral cancers. In tissue samples from patients with oral squamous cell carcinoma,...
BioCentury | Jun 7, 2017
Distillery Therapeutics

Infectious disease

...INDICATION: Viral infection Mouse studies suggest miR-31 inhibitors could help treat chronic lymphocytic choriomeningitis virus (LCMV...
...virus (LCMV) infection. In a mouse model of chronic LCMV infection, T cell-specific knockout of miR-31...
...model. TAmiRNA GmbH has the miR-31 inhibitor hsa-miR-31-5p in preclinical testing to treat osteoporosis. TARGET/MARKER/PATHWAY: MicroRNA-31 (miR-31)...
BioCentury | Jun 9, 2016
Distillery Therapeutics

Therapeutics: MicroRNA-31 (miR-31); neuronal nitric oxide synthase 1 (NOS1; nNOS)

...Fibrillation Cell culture and goat studies suggest inhibiting miR-31 could help treat atrial fibrillation (AF). miR-31...
...healthy volunteers and left ventricles of normal goats. In the atrial myocytes from patients, an anti-miR-31...
...AF. TAmiRNA GmbH has hsa-miR-31-5p , an miR-31 inhibitor, in discovery to treat osteoporosis. TARGET/MARKER/PATHWAY: MicroRNA-31 (miR-31)...
BioCentury | Jan 27, 2014
Company News

IntegraGen, University of Southampton deal

...from colorectal cancer. IntegraGen is planning to use the data to validate the cancer biomarker hsa-miR-31-3p...
BioCentury | Oct 21, 2013
Company News

IntegraGen, Assistance Publique - Hopitaux de Paris, Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale, Pa

...rights from the hospital, institutes and university for IP covering use of the oncology biomarker hsa-miR-31-3p...
BioCentury | Mar 4, 2013
Company News

IntegraGen, Lab21 deal

...SPARQ PCR technology to develop the assay to detect expression levels of the miRNA biomarker hsa-miR-31-3p...
...disclose financial details. Lab21 said the companies "will explore other opportunities for partnerships" relating to hsa-miR-31-3p...
BioCentury | Mar 31, 2011
Distillery Therapeutics

Indication: Cancer

...suggest that miR-31 could help treat cancer metastasis. In mice with metastatic breast cancer, inducing miR-31...
...development of lung metastases, regression of established metastatic tumors and improved survival compared with no miR-31...
BioCentury | Mar 18, 2010
Distillery Therapeutics

Indication: Cancer

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Lung cancer MicroRNA-31 (miR-31); LATS large tumor...
...in cell culture and in mice suggest that inhibiting miR-31 could help treat lung cancer. miR-31...
...tumor suppressors targeted by miR-31, LATS2 and PPP2R2A, promoted cell growth. Mice injected with an miR-31-knockdown...
BioCentury | Jul 9, 2009
Distillery Therapeutics

Indication: Cancer

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer MicroRNA-31 (miRNA-31) Studies in...
Items per page:
1 - 10 of 10